"Prof. Dr. Ion Chiricuţă" Oncology Institute, Cluj-Napoca, Romania.
Eur Rev Med Pharmacol Sci. 2021 Apr;25(8):3306-3315. doi: 10.26355/eurrev_202104_25742.
Although more than half a century has passed since the discovery of fluoropyrimidines, they are still used in the treatment of many types of cancer, and it is estimated that annually two million patients undergo fluoropyrimidine-based chemotherapy. The toxicity resulting from the use of fluoropyrimidines affects about 30-40% of patients, which in some cases may prove to be lethal. The key player in fluoropyrimidine toxicity is DPD activity, and patients with deficits are more likely to develop significant adverse events. In addition to genotyping DPYD variants associated with DPD deficiency, overexpression of miR-27 has also been shown to be a predictive factor for fluoropyrimidine toxicity. This review aims to relate what we know so far about the involvement of miRNA in fluoropyrimidine toxicity and to open new perspectives in this field.
尽管氟嘧啶类药物的发现已经过去了半个多世纪，但它们仍被用于治疗多种类型的癌症，据估计，每年有 200 万名患者接受氟嘧啶类药物化疗。使用氟嘧啶类药物引起的毒性约影响 30-40%的患者，在某些情况下可能是致命的。氟嘧啶类药物毒性的关键因素是 DPD 活性，而 DPD 缺乏的患者更容易发生严重的不良反应。除了与 DPD 缺乏相关的 DPYD 变异的基因分型外，miR-27 的过表达也被证明是氟嘧啶类药物毒性的预测因素。本文旨在阐述目前我们对 miRNA 在氟嘧啶类药物毒性中的作用的了解，并为该领域开辟新的视角。
